Composition containing an androgenous 11b-halogen steroid and a progestational hormone, and male contraceptive based on said composition

• US 20060100180A1
• Filed: 07/25/2003
• Published: 05/11/2006
• Est. Priority Date: 07/25/2002
• Status: Abandoned Application

• Current Assignee: Bayer Schering Pharma AG (Bayer AG)
• Original Assignee: Bayer Schering Pharma AG (Bayer AG)
• Inventors: Bohlmann, Rolf, Nubbemeyer, Reinhard, Habenicht, Ursula Freiderike
• Application Number:
  US10/522,169
• Publication Number:
  US 20060100180A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61P 15/16 Masculine contraceptives
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to a novel chemical composition containing an androgenous 11β-halogen steroid and the progestational hormone of formula (I), to a pharmaceutical composition containing said chemical composition and to a male contraceptive based on said pharmaceutical composition.

Claims

1. Composition containing an androgenic 11β

-halogen steroid, selected from the group of compounds of general formula I

2. Composition according to claim 1, characterized in that the 11β

-halogen steroid of general formula I is the compound 11β

-fluoro-17β

-hydroxy-7α

-methyl-estr-4-en-3-one.

3. Pharmaceutical composition containing a composition according to claim 1 as well as a pharmaceutically compatible vehicle and/or adjuvants.

4. Pharmaceutical composition according to claim 3, wherein the 11β

-halogen steroid of general formula I is the compound 11β

-fluoro-17β

-hydroxy-7α

-methyl-estr-4-en-3-one.

5. Male contraceptive agent containing a pharmaceutical composition according to claim 3.

6. Male contraceptive agent containing a pharmaceutical composition according to claim 4.

7. Male contraceptive agent according to claim 5, wherein the androgenic compound of general formula I is formulated pharmaceutically such that the latter can be implanted in the body of the male user over an extended period such that the androgenic compound is released continuously over this extended period to the organism of the user.

8. Male contraceptive agent according to claim 5, wherein the androgenic compound of general formula I is provided therein for oral administration.

9. Male contraceptive agent according to claim 5, wherein the gestagen therein is formulated pharmaceutically such that it is released to the body of the male user over an extended period.

10. Male contraceptive agent according to claim 9, wherein the gestagen is formulated such that the latter can be implanted in the body of the male user over an extended period, such that the gestagen is released continuously over this extended period to the organism of the user.

11. Male contraceptive agent according to claim 10, wherein the gestagen is formulated in a transdermal system.

12. Male contraceptive agent according to claim 5, wherein the gestagen is formulated for oral administration.